Perspectives on immunotherapy utilization for hepatobiliary cancers in the United States

Pedro Luiz Serrano Usón Junior, Daniel Ahn, Mohamad Bassam Sonbol, Tanios Bekaii-Saab, Mitesh J. Borad


Strategies involving immunotherapy and targeted therapies are emerging in the last years as valuable options for patients with hepatobiliary cancer (HBC) including hepatocellular carcinoma (HCC), gallbladder cancer (GBC), intrahepatic cholangiocarcinoma (ICC), and extrahepatic cholangiocarcinoma (ECC). For a long time, these diseases had only few treatment options and often with considerable toxicities (1,2). Sahara and colleagues reported an analysis of 249,913 patients with HBC identified through the National Cancer Database (NCDB) from January 2004 to December 2015.